Gregory Glenn
Overview
Explore the profile of Gregory Glenn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lenart K, Cerveira R, Hellgren F, Ols S, Sheward D, Kim C, et al.
NPJ Vaccines
. 2024 Jan;
9(1):17.
PMID: 38245545
The immune responses to Novavax's licensed NVX-CoV2373 nanoparticle Spike protein vaccine against SARS-CoV-2 remain incompletely understood. Here, we show in rhesus macaques that immunization with Matrix-M adjuvanted vaccines predominantly elicits...
2.
Liu Y, Ye L, Lin F, Gomaa Y, Flyer D, Carrion Jr R, et al.
Sci Rep
. 2023 Aug;
13(1):13705.
PMID: 37608003
No abstract available.
3.
Stertman L, Palm A, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson S, et al.
Hum Vaccin Immunother
. 2023 Apr;
19(1):2189885.
PMID: 37113023
Matrix-M™ adjuvant is a key component of several novel vaccine candidates. The Matrix-M adjuvant consists of two distinct fractions of saponins purified from the Molina tree, combined with cholesterol and...
4.
Datoo M, Natama H, Some A, Bellamy D, Traore O, Rouamba T, et al.
Lancet Infect Dis
. 2022 Sep;
22(12):1728-1736.
PMID: 36087586
Background: Malaria is a leading cause of morbidity and mortality worldwide. We previously reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified goal of 75% or greater...
5.
Rydyznski Moderbacher C, Kim C, Mateus J, Plested J, Zhu M, Cloney-Clark S, et al.
J Clin Invest
. 2022 Aug;
132(19).
PMID: 35943810
NVX-CoV2373 is an adjuvanted recombinant full-length SARS-CoV-2 spike trimer protein vaccine demonstrated to be protective against COVID-19 in efficacy trials. Here we demonstrate that vaccinated individuals made CD4+ T cell...
6.
Gorman M, Patel N, Guebre-Xabier M, Zhu A, Atyeo C, Pullen K, et al.
Cell Rep Med
. 2021 Sep;
2(9):100405.
PMID: 34485950
Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a...
7.
Datoo M, Natama M, Some A, Traore O, Rouamba T, Bellamy D, et al.
Lancet
. 2021 May;
397(10287):1809-1818.
PMID: 33964223
Background: Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over...
8.
Glenn G, Shogren R, Jin X, Orts W, Hart-Cooper W, Olson L
Compr Rev Food Sci Food Saf
. 2021 Mar;
20(3):2596-2625.
PMID: 33682364
Per- and polyfluoroalkyl substances (PFAS) have been used in food contact paper and paperboard for decades due to their unique ability to provide both moisture and oil/grease resistance. Once thought...
9.
Alter G, Gorman M, Patel N, Guebre-Xabier M, Zhu A, Atyeo C, et al.
Res Sq
. 2021 Feb;
PMID: 33619473
Recently approved vaccines have already shown remarkable protection in limiting SARS-CoV-2 associated disease. However, immunologic mechanism(s) of protection, as well as how boosting alters immunity to wildtype and newly emerging...
10.
Gorman M, Patel N, Guebre-Xabier M, Zhu A, Atyeo C, Pullen K, et al.
bioRxiv
. 2021 Feb;
PMID: 33564763
Highlights: NVX-CoV2373 subunit vaccine elicits receptor blocking, virus neutralizing antibodies, and Fc-effector functional antibodies.The vaccine protects against respiratory tract infection and virus shedding in non-human primates (NHPs).Both neutralizing and Fc-effector...